Virios Therapeutics (NASDAQ:VIRI – Get Free Report) posted its earnings results on Monday. The company reported ($0.06) EPS for the quarter, beating analysts’ consensus estimates of ($0.10) by $0.04, reports.
Virios Therapeutics Price Performance
NASDAQ VIRI opened at $0.73 on Thursday. The company has a fifty day moving average of $0.79 and a two-hundred day moving average of $1.23. The company has a market capitalization of $14.13 million, a PE ratio of -1.34 and a beta of 2.15. Virios Therapeutics has a 1 year low of $0.22 and a 1 year high of $2.42.
Institutional Trading of Virios Therapeutics
Several institutional investors and hedge funds have recently made changes to their positions in VIRI. State Street Corp purchased a new position in Virios Therapeutics during the 2nd quarter worth approximately $45,000. UBS Group AG grew its position in shares of Virios Therapeutics by 528.3% during the first quarter. UBS Group AG now owns 14,137 shares of the company’s stock worth $63,000 after acquiring an additional 11,887 shares during the last quarter. Belvedere Trading LLC acquired a new position in shares of Virios Therapeutics in the 2nd quarter valued at $25,000. McCollum Christoferson Group LLC purchased a new stake in Virios Therapeutics in the 2nd quarter valued at $42,000. Finally, Citadel Advisors LLC purchased a new stake in Virios Therapeutics in the 2nd quarter valued at $46,000. 10.96% of the stock is owned by hedge funds and other institutional investors.
Virios Therapeutics Company Profile
Virios Therapeutics, Inc, a development-stage biotechnology company, focuses on developing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response. The company's lead development candidate is the IMC-1, a fixed dose combination of famciclovir and celecoxib to treat fibromyalgia.
- Five stocks we like better than Virios Therapeutics
- Find and Profitably Trade Stocks at 52-Week Lows
- Unlocking AI investment opportunities in healthcare
- How to Know Which Cryptocurrency to Buy: A Guide for Investors
- New Disney investor propels stock to ranks of best S&P gainers
- With Risk Tolerance, One Size Does Not Fit All
- Buffett’s latest portfolio additions, trims, and cuts in Q3
Receive News & Ratings for Virios Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Virios Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.